Index

A
Activation induced cell death (AICD), 418
Adenovirus, 445
Adhesion molecules, 409
Adjuvant, 32, 411, 432
complete Freund’s, 313, 315, 318, 411, 446
incomplete Freund’s, 278, 315, 410
Adjuvant arthritis, 280
Affymetrix chips, 219, 221
Allograft rejection, 337
direct pathway of alloantigen recognition, 338
indirect pathway of alloantigen recognition, 338
Alloxan, 288
Anchor enzyme, 226
cleavage of cDNA, 229, 235
Androgen blockade, 379
Anergy
in B cell tolerance, 10
in T cell tolerance, 31, 167, 216, 272
of Treg cells, 84
Antigen processing, 26, 271, 274, 279
by TEC, 108, 279
compartments associated with, 108
Western blot analysis of, 111–112
Apoptosis
apoptotic cells in cross presentation, 33
during thymic development, 134
in induction of clonal deletion, 186
rescue from, 171
APECED, 36
Asparagine endopeptidase (AEP), 277
Autoimmune disease
etiology of, 271–283
spontaneous, 285–311
Autoimmune regulator (AIRE), 2, 31, 108, 131, 141, 294, 298, 377
B
BAFF, in B cell tolerance, 10
BB rat, 409
B cells
as APC, 12
apoptosis, 11
depletion, 11
in hyperacute rejection, 12
tolerance, 9–12
B cell receptor (BCR)
editing, 10
somatic hypermutation, 10
Bcl-2, 301
Bcl-2-interacting mediator of cell death (BIM), 2
Blastocyst, 74
Bone marrow, 407
as a source of CD34+ cells, 11
enrichment of CD11c+ cells from, 50–51
in B cell development, 9
transplantation, 166, 391–403, 432
Bone morphogenetic proteins, 147–148
C
Cancer immunotherapy, 281
Carboxyfluorescein diacetate succinimidyl ester (CFSE), 258, 316, 356
labeling of cells with, 367, 371
use in assessing T cell proliferation in vitro, 320
use in monitoring CTL function in vivo, 365–376
CD4+CD25+ T cells see Regulatory T cells
CD4+CD45\textsuperscript{high} T cells, 328
purification of, 329, 330–331
CD8+CD28\textsuperscript{-} T cells see CD8+ regulatory T cells
CD8\textsuperscript{+} regulatory T cells, 7
CD34\textsuperscript{+} progenitor cells, 29, 198
Cell tracker blue, 266
Cell tracker orange, 258
Central nervous system (CNS), 313, 411
Chemokines
in dendritic cell migration/recruitment, 28, 465
in thymocyte migration, 130
in type 1 diabetes, 299–300
Chimera, chick-quail, 133, 139
Cholera toxin, 216, 217
analysis of in FTOC, 179–182
escape from, 276, 279, 281
in mixed chimerism, 13
Clonal exhaustion, in mixed chimerism, 13
Clonal expansion, 200, 365
Collagen
type I, 253
type II, 410, 452
Collagen-induced arthritis, 443
Common myeloid progenitor, 29, 48
Common lymphoid progenitor, 29, 48
Complement, 314
Concanavalin A, 166
Co-receptor, 409
blockade, 417
Co-stimulation, 409
B7-CD28 pathway, 14, 366, 392
blockade, 14, 391–403, 417, 418, 419
CD40-CD154 pathway, 3, 392
control by Treg, 36
inducible co-stimulator ligand (ICOSL), 60
in pathogenesis of type 1 diabetes, 292–294
Coxsackie virus, 288
C-peptide, 348
Crohn’s disease, 327
Cross presentation of antigen, 3, 30
Cyclophosphamide
in establishing mixed chimerism, 13
in induction of type 1 diabetes, 289
Cyclosporine A, 418
Cytokinin see Keratin
Cytosine-poly-guanine oligodeoxynucleotide (CpG)
in dendritic cell maturation, 8
Cytotoxic T lymphocyte (CTL), 365
Cytotoxic T lymphocyte antigen (CTLA) 4
expression by Treg, 432
in Treg function, 5
D
Decoy receptor 3 (DCR3), 293
Dectin-1, 409
Delayed type hypersensitivity (DTH), 337, 443
Demyelination, 313
Dendritic cell
CD8\textsuperscript{α}+ dendritic cells, 30, 48
DC1, 28
DC2, 28
differentiation from bone marrow, 218, 228, 253, 443
differentiation from ES cells, 67–68, 229
gene expression profiling of, 215–224
Index 471

in RTOC, 186, 195
interferon α-producing dendritic cells (IDC), 28
regulatory properties, 34
licensed, 33
maturation, 26–27
  in response to:
    CD40L, 26
    LPS, 26, 68–69
    necrotic cells, 33
    NKT cells, 33
    TLR agonists, 33
    TNFα, 216
mucosal, 27
myeloid, 3, 216
plasmacytoid, 3
  involvement in tolerance, 4
  regulatory, 3, 34
  differentiated DC (diffDC), 34
  semi-mature, 216
subsets, 26–30
thymic, 129, 163, 165, 167, 198, 254, 348
tolerogenic, 168
  iteration with Treg, 8–9, 216
tumor-derived, 460
vaccination, 38
2-Deoxyguanosine (2-dGuo), 187
  in preparation of alymphoid fetal thymi, 189–190, 347
Determinant
cryptic, 274, 280, 281, 292
dominant, 280, 313, 460
spreading, 279, 280
subdominant, 274, 280, 281
Dexamethasone
  in inhibition of dendritic cell maturation, 8, 33
Diabetes
  induction of, 344–345
  type 1, 285–311, 409
    adoptive transfer of, 289
    pathogenesis of, 287
DiGeorge syndrome, 142
Donor specific transfusion (DST), 407, 418, 419
  in induction of dominant tolerance, 414
E
E-cadherin
  role in adhesion of Langerhan’s cells, 28
Embryoid bodies (EB), 60
cystic, 70
simple, 70
Embryonic stem (ES) cells, 59, 73
  cloning of, 65–66
  differentiation to EB, 61–62, 66–67
  from NOD mice, 291
  genetic modification of, 61, 64–65
  maintenance of, 61
  passage of, 63
Endocytosis
  receptor mediated, 26
Endocytic receptors
  DC-SIGN, 33
Endosome, late, 443
Epitope see Determinant
Experimental autoimmune
  encephalomyelitis (EAE), 3, 275–276, 281, 411
immunotherapy of, 313–326, 405
  induction by active immunization, 315–316, 318
Induction by adoptive transfer of T cells, 317, 321–322
Exosomes, 30, 443–455
  affect on MLR, 451
  affect on DTH, 452
  affect on CIA, 452
  characterization of, 446–447, 449–451
  preparation from DC, 445, 447–448
  visualization by electron microscopy, 445, 448
Extracellular matrix (ECM), 253
in thymus, 129
receptors for, 129
Eya1, 143–144

F
Fas, 2
in pancreatic β cell destruction, 293
in SLE, 411
Fas-ligand, 443, 445
Feeder cells see Primary embryonic fibroblasts
Fetal thymus organ culture (FTOC), 49, 50, 53–54, 171-184, 380
staining, 51
Fibroblast, 166, 229
primary embryonic, 74–76
preparation, 60–61, 62–63
Fibroblast growth factors, 148–149
FGF 7, 139
FGF 8, 142
FGF 10, 139, 142
Flagellin, 216
Flt3-L
in B cell development, 74
in DC recruitment, 458
in DC expansion in vivo, 460–463
in T cell development, 78
Foxp3, 3, 36, 83, 84, 298, 314, 408, 432
Foxn1, 134, 145
role in thymic epithelial development, 145–147
FTY720, 419

G
Gastritis, 285
Gene expression signatures, 244
Genetic modification
of dendritic cells, 59
of embryonic stem cells, 64–65
Glutamic acid decarboxylase (GAD), 285, 295
Goblet cells, 328
Graft-vs-host disease (GVHD), 3, 31, 84, 381, 432

Index
risk factor in mixed chimerism, 13
Graft-vs-leukemia (GVL) reaction, 166
Granulocyte-macrophage colony stimulating factor, 48, 52, 55, 257, 445
in directed differentiation of ES cells, 62, 68, 70
Growth hormone, 379

H
H2-DM, 107
as a marker of endosomes in TEC, 115–117
isolation of H2-DM+ compartments, 117–118
H-2M, 279
Heat shock protein (hsp) 65, 280
Helicobacter spp, 333
Hemolytic anemia, 285
Hemangioblast, 73
Hematopoietic cell chimerism see Mixed chimerism
Hematopoietic progenitors see Hematopoietic stem cell
Hematopoietic stem cell, 73, 163, 253
transplantation, 381
Hen eggwhite lysozyme (HEL), 274
Heterologous immunity, 418
HIV, 166, 379
Homeostatic T cell proliferation, 199, 377, 378, 386, 432
Hoxa3, 142–143

I
IA-2, 285, 295
Imidazoquinolines, 216
Immune privilege, 444
Immunodeficiency, 145
Immunodominance, 272–275
Immunological ignorance, 272
Immunological memory, 33, 215
memory T cells, 378, 384–385, 418, 419
Immunological synapse, 409
Index

Indoleamine 2,3-dioxygenase, 60
  in tryptophan catabolism, 34
Inflammatory bowel disease, 298, 327–335
  induction of, 331–333
  monitoring of, 331–333
Inflammatory stimuli, 215
Insulin, 285, 295
Insulin-like growth factor (IGF)-1, 379
Insulitis, 285
  detection of, 287–288
Interferon α see Type I interferon
Interferon
  type I, 4
    in generation of Tr1 cells, 85
  type II
    in NKT cell function, 6
Interferon γ see Type II Interferon
Interleukin 1β (IL-1β)
  in dendritic cell stimulation, 217
Interleukin 2 (IL-2)
  in generation of CD4+CD25+ Treg, 298, 431
  in pathogenesis of type 1 diabetes, 292
Interleukin 3 (IL-3)
  in directed differentiation of ES cells, 62, 68, 70
Interleukin 4 (IL-4)
  in NKT cell function, 6
  in semi-maturation of DC, 216
  in generation of bone marrow derived DC, 257
Interleukin 6 (IL-6)
  intrathymic production of, 380
Interleukin 7 (IL-7)
  in B cell development, 74
  in T cell development, 78, 129–130
  secretion by TEC, 129, 380
Interleukin 10 (IL-10)
  in inhibition of dendritic cell maturation, 8
  in modulation of dendritic cell function, 228
  in pathogenesis of type 1 diabetes, 292
  in NKT cell function, 6
  in regulatory dendritic cell function, 34
  in Treg function, 5, 36, 80
  tumor derived, 458
Interleukin 12 (IL-12), 366
  secreted by dendritic cells, 27
Interleukin 13 (IL-13)
  in NKT cell function, 6
Intravital two photon imaging, 355–363
IPEX syndrome, 36
Islets of Langerhans, 337, 351
  isolation of, 342–343
  transplantation under the kidney capsule, 343–344
J
Jugular vein
  canulation of, 358–359
K
Keratin, 129
  keratin 5, 109, 135–137
  keratin 8, 109, 135–137, 380
Keratinocyte, 166
Kidney capsule
  as a site of transplantation, 164, 339, 347–353
L
Langerhans cell, 28, 48
Leishmania mexicana promastigote, 217
Leukemia inhibitory factor (LIF)
  in the maintenance of pluripotency, 65
Linked suppression, 406, 415–416
Lipopolysaccharide (LPS), 49, 216, 217
Lymph node, 254, 457
  inguinal, 356
  intravital T cell imaging in, 355–363
popliteal, 356, 358, 362
exposure of, 359–361
Lymphocytic choriomeningitis virus (LCMV), 172, 418
derived peptide, 173
Lympho-epithelial cross-talk, 139
role of Foxn1, 146
Lymphopenia, 35, 200, 377, 386, 419
Lymphoproliferative autoimmune syndrome, 5
Lymphotoxin β (LTβ), 141
Lysosome, 444

M
Macrophone, 278, 285
in pathogenesis of EAE, 313
thymic, 129
depletion of, 188, 191
Macrophage colony stimulating factor (M-CSF), 49, 52, 74
Macropinocytosis, 26
Magnetic resonance imaging (MRI), 348
Marginal zone, 28
Mass spectrometry, 16
Mast cell, 444
Matrix
3-dimensional, 163, 164
3-dimensional collagen matrices, 253–269
M-cells, 28
Mesenchymal cells, 125, 129
in formation of the thymic capsule, 131
secretion of growth factors, 139
Mesoderm, 73, 80
Microarray, 215–224
Microbial associated molecular patterns (MAMPs), 216
Microchimerism, 13
Mitosis, 199
Mixed chimerism, 12–13, 31, 391–403, 414, 419
detection of, 396–397
Mixed leukocyte reaction (MLR), 166, 431, 434, 443
Monocytes, 26
differentiation of dendritic cells from, 29
Mouse lysozyme, 277–278
Multiple sclerosis, 313, 411
Mycophenolate mofetil, 400, 419
in inhibition of dendritic cell maturation, 8
Mycoplasma, 467
Myelin basic protein (MBP), 274, 275, 276, 277, 411
encephalitogenic peptides from, 315
Golli-MBP, 275
Myeloablative conditioning, 391

N
Natural Killer T (NKT) cells, 6, 84
role in type 1 diabetes, 6, 286, 297
Negative selection see Clonal deletion
Neomycin resistance gene, 65
Neural crest cells (NCC), 133, 138
role of Pax3 in survival and migration, 144
Noggin, 147–148
Non-myeloablative conditioning, 391
Non-obese diabetic (NOD) mouse, 84, 279, 285–311, 339, 345, 408, 409, 411, 417
Notch
in thymocyte maturation, 130, 186
ligands
Delta-like 1, 73–74, 130
Delta-like 4, 130
Jagged 1 and 2, 130
Nude mouse, 134, 348

O
Oncostatin M, 380
Oophoritis, 285
OP9 bone marrow stromal cell line, 73
OP9-DL1, 74, 75–77, 186
### Index

#### P
- Pancreatic β cells, 286
- Pannus formation, 411
- Parathyroid, 131
  - GCM2 expression by, 131, 145
- Parkinson’s disease, 339
- Pax1, 143
- Pax3, 144
- Pax9, 143
- PD-1 ligand, 146
- Peptidoglycan, 216
- Peripheral blood mononuclear cells (PBMC), 86, 165
  - AC133+ PBMC, 165
- Pertussis toxin, 216, 217, 315, 319, 321
- Pluripotency, 59, 65
- Phagocytosis, 26
- Pharyngeal region
  - pharyngeal arches, 131–133
  - role of Tbx1 in patterning, 142
  - pharyngeal clefts, 131–132
  - pharyngeal pouches, 131–132
- Phytohemagglutinin (PHA), 165, 166
- Placenta, 444
- *Pneumocystis carinii*, 333
- Positive selection, 74, 146, 164, 166, 171, 185–186, 198, 254, 347, 378
  - analysis of in FTOC, 178–179
  - of CD4+CD25+ Treg, 35, 295
- Positron emission tomography (PET), 348
- Pre-immunocyte, 47
  - enrichment from bone marrow, 49
- Prostaglandins, 3, 216, 217
- Prostatitis, 285
- Proteomics, 15–16

#### Q
- Qa-1
  - in function of CD8+ regulatory T cells, 7

#### R
- Rapamycin, 400, 419
  - in inhibition of dendritic cell maturation, 8
- Rat insulin gene promoter, 291
- Reaggregate thymus organ cultures (RTOC), 74, 130, 185–196
- Recent thymic emigrants, 197, 207, 384
- Regulatory T cell (Treg), 2, 59, 215, 225, 313, 405, 457
  - adaptive Treg
    - expansion of, 418
  - CD4+CD25+ Treg, 35–37, 416
  - in prevention of autoimmunity, 84, 286
  - in prevention of IBD, 327
  - in prevention of type 1 diabetes, 297–299
  - naturally occurring Treg, 4, 83, 225, 229, 431
  - adoptive transfer of, 431–441
  - cloning of, 89–90
  - cytokine production by, 91
  - expansion of, 89–90, 405
  - ex vivo stimulation of, 437
  - in vitro stimulation of, 435–437
  - isolation of, 86–89
  - phenotypic analysis of, 90–91
  - suppressive activity of, 91–92
  - positive selection of, 35–36, 168, 377
- Reticulocyte, 444
- Retinoic acid, 149–150
- Rheumatoid arthritis, 409, 410–411, 452

#### S
- Serial analysis of gene expression (SAGE), 225–251
- Sequestration
  - intramolecular, 271, 272–273
  - of self-antigen, 272
- Severe combined immune deficiency (SCID) mice, 327
use for generation of “humanized” mice, 15
Sialoadenitis, 285
Six1, 143–144
Sonic hedgehog (Shh), 150
Stem cell factor (SCF), 129
Streptozotocin, 288, 339
Superantigen, 295, 395, 400
Syncytiotrophoblast, 444
Systemic lupus erythematosus (SLE), 411
role of interferon γ, 16

T
Tacrolimus, 418
Tagging enzyme, 226
release of SAGE tags, 230, 236
Tbx1, 141–142
T cell receptor (TCR)
αβTCR, 165, 185
γδTCR, 165
affinity, 273
editing, 31
excision circles (TREC), 163, 197–213, 378
as an estimate of thymic function, 200–201, 384
detection of, 202–203
generation of, 198–199
hypervariable regions, 198
Tetramethylrhodamine-dextran, 362
Tetramer
of MHC class I peptide complexes, 374
T helper 1 (Th1) cells
in type 1 diabetes, 296–297
T helper 2 (Th2) cells, 443
in type 1 diabetes, 296–297
T helper 3 (Th3) cells, 37
Thymectomy, 35
Thymic aplasia, 138
Thymic atrophy see Thymus involution
Thymic epithelial cells (TEC), 107, 125, 171, 198, 348, 379
cortical (cTEC), 107, 127, 378
in positive selection of Treg, 35
endodermal origin, 133–134
establishment of TEC lines, 113–115
expression of FgfR2IIb, 139
in positive selection, 186
keratin expression by, 115, 129
medullary (mTEC), 107, 127, 163, 278
AIRE expression by, 31, 108, 131, 141, 279, 377
phenotype, 128
progenitors, 134–135
subcapsular/subtrabecular, 127
tolerogenicity of, 167
Thymic nurse cells, 128, 378
Thymocytes
CD4+CD8− cells, 50, 164, 166, 198
isolation, 51
TN1 cells (CD44−CD25+), 135
TN2 cells (CD44−CD25+), 79
CD4+CD8+ (DP) cells, 127, 165, 166, 173, 185, 198, 380
isolation from neonatal thymus, 191–192
CD4+CD8− (SP) cells, 127, 164, 165, 166, 172, 173, 198, 380
CD4+CD8+ (SP) cells, 127, 164, 165, 166, 172, 173, 198, 380
Thymopoiesis, 197, 198, 377, 378, 379, 380, 381–385, 386
Thymus
accessory, 138
cortex, 125, 138
corticomedullary junction, 127, 129, 146
in development of Treg, 4
involution, 166, 200, 377–390
medulla, 31, 125, 138
microenvironment, 73, 163, 185
organogenesis, 125–162
structure, 126
Thyroiditis, 285
Tissue engineering, 164
Tolerance
Central tolerance see Clonal deletion
dominant tolerance, 59, 405–429
confirmation of, 415–417
infectious, 405, 406, 416
peripheral, 225, 294, 347
transplantation, 337–346, 391–403,
405, 434–435
Toleranceosome, 444
Toll-like receptors (TLR), 457, 458
expression by β cells, 299
epression by Treg, 432
in B cell activation, 10
in dendritic cell activation, 216
Total body irradiation (TBI), 391,
395–396
Toxoplasma gondii, 444
Transcriptome, 246
Transferrin receptor, 444
Transplantation
heart, 337, 408, 444
islet, 337, 340–341, 342–344, 408
kidney, 337, 408
liver, 408
neuronal, 339
skin, 337, 338–339, 340, 341–342,
408
Transporter associated with antigen
processing (TAP)-1, 171, 174
T regulatory 1 (Tr1) cells, 6, 37, 83,
225, 229
alloantigen specific, 94–96
cloning of, 96–97
cytokine production by, 99
induction of, 93–94
phenotype of, 99
role in inflammatory bowel disease,
6, 85
role in airway hyperreactivity, 85
role in allograft rejection, 85
suppressive function of, 100–102
Transforming growth factor (TGF) β
in generation of CD4+CD25+ Treg,
298

in induction of Foxp3 expression,
299
in NKT cell function, 6
in Treg function, 5, 36, 84
in pathogenesis of type 1 diabetes,
292
tumor derived, 458
Treg see Regulatory T cell
Tumor-associated antigen
breaking of tolerance to, 457–468
Tumor necrosis factor α (TNFα), 3, 130
in semi-maturation of dendritic cells,
216
in pathogenesis of type 1 diabetes,
292
U
Ulcerative colitis, 327
V
Vaccination
to tumor associated antigens, 38
V(D)J recombination
in B cell receptor gene rearrangement,
9
Velocity
of cells in 3D-matrices, 253, 261,
265
Vitamin D3 (1α,25-dihydroxyvitamin D3)
in inhibition of dendritic cell
function, 8, 33
in modulation of dendritic cell
function, 229
W
Wnt family, 151
X
Xenoantigens, 167
Xenograft, 406
Z
ZAP70, 2, 409
Zymosan, 216, 217